Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
BAUSCH + LOMB ET NICOX ANNONCENT L’APPROBATION DE LA FDA POUR VYZULTA™ (SOLUTION OPHTALMIQUE DE LATANOPROSTÈNE BUNOD), 0,024%

July 18, 2021

View Press Release Corporate presentation Contact us
Previous